Dyne Therapeutics, Inc. financial data

Symbol
DYN on Nasdaq
Industry
Pharmaceutical Preparations
Location
1560 Trapelo Road, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.19K % +12.2%
Debt-to-equity 14.8 % -27.7%
Return On Equity -68.9 % +13.5%
Return On Assets -60 % +9.25%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 100M shares +64.5%
Common Stock, Shares, Outstanding 100M shares +64.1%
Entity Public Float 504M USD +133%
Common Stock, Value, Issued 10K USD +66.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 221M USD +34.3%
General and Administrative Expense 50.2M USD +66.7%
Operating Income (Loss) -271M USD -39.3%
Net Income (Loss) Attributable to Parent -258M USD -36.1%
Earnings Per Share, Basic -3.6 USD/shares -6.2%
Earnings Per Share, Diluted -3.6 USD/shares -6.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 608M USD +263%
Assets, Current 792M USD +272%
Property, Plant and Equipment, Net 5.02M USD -6.29%
Operating Lease, Right-of-Use Asset 26.6M USD -12.9%
Assets 826M USD +228%
Accounts Payable, Current 1.89M USD -30.7%
Employee-related Liabilities, Current 8.18M USD +119%
Liabilities, Current 29.8M USD +47.1%
Operating Lease, Liability, Noncurrent 20.9M USD -13.9%
Liabilities 50.7M USD +13.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -240K USD -329%
Retained Earnings (Accumulated Deficit) -763M USD -50.9%
Stockholders' Equity Attributable to Parent 775M USD +275%
Liabilities and Equity 826M USD +228%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -78.5M USD -67.4%
Net Cash Provided by (Used in) Financing Activities 408M USD +1317%
Net Cash Provided by (Used in) Investing Activities -180M USD -765%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 100M shares +64.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 150M USD +1573%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 610M USD +259%
Deferred Tax Assets, Valuation Allowance 146M USD +28.3%
Deferred Tax Assets, Gross 152M USD +24%
Operating Lease, Liability 27.4M USD -10.1%
Payments to Acquire Property, Plant, and Equipment 191K USD -17%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -258M USD -37%
Lessee, Operating Lease, Liability, to be Paid 32.8M USD -12.6%
Property, Plant and Equipment, Gross 11.1M USD +13%
Operating Lease, Liability, Current 4.78M USD +1.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.99M USD +3.01%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.85M USD +2.41%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.36M USD -23.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.14M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 57.5M USD -4.21%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.3M USD +2.99%
Additional Paid in Capital 1.54B USD +116%
Depreciation, Depletion and Amortization 1.65M USD +4.9%
Deferred Tax Assets, Net of Valuation Allowance 6.01M USD -31.7%
Share-based Payment Arrangement, Expense 37.2M USD +119%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%